Objective: The object of the study was to examine the major pharmacokinetic parameters after a single application of a complex drug preparation for veterinary use based on fipronil, praziquantel, moxidectin, and pyriproxyfen in cats and dogs.
Materials and Methods: For dogs, the drug preparation was administered spot-on solution in the following dosage of active pharmaceutical substances: fipronil 27.0 mg/kg body weight (bwt), praziquantel 10.8 mg/kg bwt, moxidectin 6.75 mg/kg bwt, and pyriproxyfen 5.4 mg/kg bwt; for cats, the dosage was the following: fipronil 43.2 mg/kg bwt, praziquantel 17.28 mg/kg bwt, mox-idectin 4.32 mg/kg bwt, and pyriproxyfen 8.64 mg/kg bwt. The blood samples were taken from dogs and cats. The principle of the method for determining praziquantel, trans-4-hydroxyprazi-quantel, pyriproxyfen, and fipronil in serum samples was chromatographed in a high-pressure liquid chromatograph with detection by means of a mass-spectrometric detector. The moxidectin content of the blood was detected by high-performance liquid chromatography.
Results: The drug preparation active substances: praziquantel, fipronil, and moxidectin are absorbed into the blood of dogs and cats. The penetration of praziquantel into the systemic circulation and further into organs and tissues was proved. After topical administration, moxidectin is absorbed and distributed systemically and is slowly removed from the plasma, which manifests itself in detectable concentrations of moxidectin in the blood for 1 month.
Conclusion: The present results of pharmacokinetic investigations may promote to the determination of effective therapy strategy and prophylaxis of parasitic diseases in dogs and cats.
Fipronil; moxidectin; pharmacokinetics; praziquantel; pyriproxyfen
Potential neuroprotection by nobile Lindl alkaloid in Alzheimer's disease models.
Li DD, Zheng CQ, Zhang F, Shi JS
Neural regeneration research. 2022; 17(5): 972-977
Phase 1 studies comparing safety, tolerability, pharmacokinetics and pharmacodynamics of HLX01 (a rituximab biosimilar) to reference rituximab in Chinese patients with CD20-positive B-cell lymphoma.
Shi Y, Zhang Q, Han X, Qin Y, Ke X, Su H, Liu L, Fu J, Jin J, Feng J, Hong X, Zhang X, Wu D, Jiang B, Dong X
Chinese journal of cancer research = Chung-kuo yen cheng yen chiu. 2021; 33(3): 405-416
A randomized, double blind, single dose, comparative study of the pharmacokinetics, safety and immunogenicity of MB02 (bevacizumab biosimilar) and reference bevacizumab in healthy male volunteers.
Sinn A, Garcia-Alvarado F, Gonzalez V, Huerga C, Bullo F
British journal of clinical pharmacology. 2021; ():
Influence of and Polymorphisms on the Pharmacokinetics of Teneligliptin in Humans.
Park JW, Kim KA, Kim JM, Park IH, Park JY
Frontiers in pharmacology. 2021; 12(): 736317
N-(anilinoethyl)amide melatonergic ligands with improved water solubility and metabolic stability.
Ferlenghi F, Mari M, Gobbi G, Elisi GM, Mor M, Rivara S, Vacondio F, Bartolucci S, Bedini A, Fanini F, Spadoni G
ChemMedChem. 2021; ():